Article

Pulmonary and Cutaneous Sarcoidosis Associated With Interferon Therapy for Melanoma

Author and Disclosure Information

Interferon alfa is widely used as adjuvant therapy for melanoma. Numerous side effects have been attributed to interferon alfa. Interferon alfa–induced sarcoidosis is an uncommon event. We report the third case of pulmonary and cutaneous sarcoidosis in the course of interferon alfa treatment for melanoma. Most cases of sarcoidosis have been reported during treatment of chronic hepatitis C. The prognosis is good with discontinuation of treatment. Other than interferon therapy, sarcoidosis or granulomatosis reactions rarely have been reported in malignant melanoma. We discuss and review the literature on the physiopathology of sarcoidosis brought on by interferon therapy.


 

Recommended Reading

First SCC Calls for Change in Immunosuppression
MDedge Dermatology
Metastasizing Cancer Cells Face Harsh Conditions
MDedge Dermatology
Gleevec May Be Effective for Mucosal Melanomas
MDedge Dermatology
Data Watch: American Adults' Beliefs About Sun Exposure
MDedge Dermatology
Malignant Excisions Are Becoming More Common
MDedge Dermatology
Actinic Keratoses: Reclassification Spurs Debate
MDedge Dermatology
Australian Study Shows High Turnover of Actinic Keratoses
MDedge Dermatology
Some Topical Polyphenols May Have a Role in AK Treatment
MDedge Dermatology
Anticancer Agents Causing Unbearable Skin Toxicity
MDedge Dermatology
Immunostaining Helps Classify Extramammary Paget Disease
MDedge Dermatology